Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9-ING-41 plus Carboplatin in Advanced Salivary Gland Carcinoma
NCT04832438Phase 2Withdrawn
- Sponsor
- Actuate Therapeutics
- Start
- Dec 2030
- Primary completion
- Jun 2033
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of elraglusib in salivary gland carcinoma (SGC), adenoid cystic carcinoma (ACC), sponsored by Actuate Therapeutics. Planned start Dec 2030; status: withdrawn.
02
Drugs
elraglusib
03
Conditions
salivary gland carcinoma (SGC)adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT04832438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04832438.